Tag Archive > Significant Improvement

EANS-Adhoc: AGRANA Beteiligungs-AG / AGRANA increases earnings in first three quarters of 2011|12

——————————————————————————– ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. ——————————————————————————– 9-month report 22.12.2011 Vienna, 22 December 2011 For the first nine months of 2011|12, AGRANA reports an increase in consolidated revenues compared to the prior year from approx. EUR 1,624 [...]

Continue reading

, , , , , , , , , , , , , , , , , , ,

EANS-Adhoc: BENE AG / Bene announces third quarter 2011/12 results (with document)

——————————————————————————– ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. ——————————————————————————– quarterly report 14.12.2011 – Break-even achieved in third quarter – Sales rose by 10.1 % – Clear increase in sales and significant improvement in earnings expected for the full [...]

Continue reading

, , , , , , , , , , , , , , , , , , ,

Pfleiderer posts significant growth of revenue and operating profit in first half of 2011

Neumarkt (ots) – – Adjusted EBITDA for first six months improves by 38 percent to 54.1 million euros – Continuing operations already break even before taxes assuming implementation of restructuring in first half of 2011 – First-half revenue up by 9.4 percent to 595 million euros (continuing operations, excluding business in North America) – European [...]

Continue reading

, , , , , , , , , , , , , , , , , , ,

EANS-News: Epigenomics AG reports EpiproColon® 2.0 finds 95% of cancers in clinical study

——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– Company Information/New Products/molecular diagnostics Subtitle: Study provides clinical evidence for CE-marking in Europe and paves way to US pivotal clinical trial for submission to FDA before year-end Berlin, Germany, and Seattle, WA, USA, September 19, 2011 [...]

Continue reading

, , , , , , , , , , , , , , , , , , ,

EANS-Adhoc: AGRANA Beteiligungs-AG / AGRANA increases annual guidance following strong Q1 2011|12

——————————————————————————– ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. ——————————————————————————– 3-month report 22.06.2011 22 June 2011 In the first quarter of its 2011|12 financial year, AGRANA boosted it pre- exceptionals operating profit from around EUR 34m to approximately EUR [...]

Continue reading

, , , , , , , , , , , , , , , , , , ,

EANS-Adhoc: BENE AG / Earnings of the first quarter of 2011/12.

——————————————————————————– ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. ——————————————————————————– 3-month report 22.06.2011 – Trend reversal confirmed – Sales increase of 18.5 % – Significant improvement in all key earnings figures – Gross profit margin continued to rise Vienna/Waidhofen [...]

Continue reading

, , , , , , , , , , , , , , , , , , ,

DACOGEN(R) (decitabine) Showed an Overall Survival Advantage Compared With the Accepted Standard Therapies in Older Patients With Newly Diagnosed De Novo or Secondary Acute Myeloid Leukemia

Chicago and Beerse, Belgium (ots/PRNewswire) – – Data From DACO-016 Trial at 2011 American Society of Clinical Oncology Annual Meeting – NB: Data in this release corresponds to ASCO abstract 6504 Data from the DACO-016 trial of DACOGEN(R) (decitabine) presented today at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO), demonstrate [...]

Continue reading

, , , , , , , , , , , , , , , , , , ,

EANS-Adhoc: voestalpine AG /Annual Report 2010/11: annual profit triples to around 600 EURm

——————————————————————————– ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. ——————————————————————————– annual report 31.05.2011 Further improving dynamics of global economy. Emerging markets are driver of economic upturn, recovery of Europe based on exports, except peripheral areas in the South and [...]

Continue reading

, , , , , , , , , , , , , , , , , , ,

EANS-Adhoc: BENE AG / Bene with significant improvement in earnings and slight decrease in sales in the financial year 2010/11 (with document)

——————————————————————————– ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. ——————————————————————————– annual report 19.05.2011 – EBITDA positive again – EBIT increased by EUR 5.8 million – Gross profit margin further improved to 53.8 % – Clearly positive operating cash flow [...]

Continue reading

, , , , , , , , , , , , , , , , , , ,

SNCB Logistics Selects Quintiq and Ab Ovo for the Full Resource Planning Cycle

‘S- HERTOGENBOSCH, The Netherlands, May 12, 2011 (ots/PRNewswire) – SNCB Logistics, an independent international logistics group, have chosen Quintiq and Ab Ovo to deliver a planning solution that supports the full resource planning cycle, from long term planning to real-time execution management. The solution will integrate the planning and scheduling of SNCB’s line locomotives, shunting [...]

Continue reading

, , , , , , , , , , , , , , , , , , ,

EANS-News: Balda AG / Progress made with the reorganisation of the Group in the first quarter of 2011

New appointments to management positions / Very solid financial position allows Balda to finance an acquisition by its own means ——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– quarterly report Subtitle: New appointments to management positions / Very solid financial position allows Balda to [...]

Continue reading

, , , , , , , , , , , , , , , , , , ,

EANS-News: Progress-Werk Oberkirch AG / PWO reports strong first quarter of 2011

– High growth in revenue and total output – Operating EBIT margin rises significantly before currency effects – 2011 forecast confirmed ——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– 3-month report Subtitle: – High growth in revenue and total output – Operating EBIT margin [...]

Continue reading

, , , , , , , , , , , , , , , , , , ,

EANS-News: LPKF enjoys continued success Laser specialist with record levels of revenue and earnings

——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– annual result/Major order Garbsen (euro adhoc) – Garbsen, 30 March 2011 – With a boost in earnings of 149%, LPKF produces its best performance to date in the 2010 financial year. The shareholders of the Garbsen-based [...]

Continue reading

, , , , , , , , , , , , , , , , , , ,

Nordion Reports First Quarter 2011 Financial Results

Ottawa (ots/PRNewswire) – Highlights: – Extended sales contract with major customer Lantheus Medical Imaging until 2013 – Announced return of cash to shareholders through dividend and Normal Course Issuer Bid (NCIB) – Achieved cost savings following completion of strategic repositioning Nordion reports in U.S. dollars unless otherwise specified Nordion Inc. , a leading provider of [...]

Continue reading

, , , , , , , , , , , , , , , , , , ,

Sanofi-aventis: Investigational Compound Once-Daily Lixisenatide Demonstrated Significant Improvement in Glucose Control in Patients With Type 2 Diabetes

Paris (ots/PRNewswire) – Sanofi-aventis announced today the first Phase III results of the GetGoal clinical trial program assessing the efficacy and safety of lixisenatide, a once-daily GLP-1 receptor agonist, as monotherapy in patients with type 2 diabetes. These results were presented at the European Association for the Study of Diabetes (EASD) 46th Annual Meeting in [...]

Continue reading

, , , , , , , , , , , , , , , , , , ,

prev posts